Journal: Thoracic Cancer

Article Title: FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

doi: 10.1111/1759-7714.14750

Figure Lengend Snippet: Downregulation of FBP1 in gefitinib‐resistant lung cells. (a) Simplified β‐elemene‐key target network. (b) Heatmap depicting the differentially expressed genes between parental HCC4006 cells and gefitinib‐resistant HCC4006 cells based on GSE123066 datasheets. (c) Venn diagram of β‐elemene targets and the downregulated genes in gefitinib‐resistant HCC4006 cells from GSE123066 datasheets. (d) The mRNA and protein levels of FBP1 in PC9, PC9/GR, HCC827, and HCC827/GR cells. (e). The mRNA and protein levels of FBP1 in PC9/GR and HCC827/GR cells with or without 10 μg/ml β‐elemene treatment. (f) Representative images of the dose‐dependent increase in FBP1 expression after β‐elemene treatment. ** p < 0.01

Article Snippet: The β‐elemene injection (National Medical Product Administration Approval Number: Chinese medicine H10960114) was obtained from Dalian Huali Jingang Pharmaceutical (Dalian, China).

Techniques: Expressing

Journal: Thoracic Cancer

Article Title: FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

doi: 10.1111/1759-7714.14750

Figure Lengend Snippet: FBP1‐mediated sensitivity to gefitinib in PC9/GR and HCC827/GR cells. PC9/GR and HCC827/GR were transduced with SCR or shFBP1 (shRNA targeting FBP1) and then treated with 10 μg/ml β‐elemene for 24 h for subsequent experiments. (a) The protein level of FBP1 was measured in PC9/GR and HCC827/GR cells. (b) Growth curve, (c) apoptosis level, (d) colony formation, and (e) IC50 values of gefitinib in PC9/GR and HCC827/GR cells as indicated treatment. ** p < 0.01, compared with PBS; # p < 0.05, compared with SCR

Article Snippet: The β‐elemene injection (National Medical Product Administration Approval Number: Chinese medicine H10960114) was obtained from Dalian Huali Jingang Pharmaceutical (Dalian, China).

Techniques: Transduction, shRNA

Journal: Thoracic Cancer

Article Title: FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

doi: 10.1111/1759-7714.14750

Figure Lengend Snippet: β‐elemene regulates gefitinib resistance through the FBP1/STAT3 axis in PC9/GR and HCC827/GR cells. (a and b) The protein expression of STAT3 and p‐STAT3 (Tyr705) in PC9/GR (a) and HCC827/GR (b) cells after β‐elemene treatment, followed by or without 0.5 μM colivelin treatment in the nucleus. The protein expression of BCL‐2, Bax, and cleaved caspase‐3 in PC9/GR (a) and HCC827/GR (b) cells after β‐elemene treatment, followed by or without colivelin treatment in the cytoplasm. (c) Growth curve, (d) apoptosis level, (e) colony formation, and (f) IC50 values of gefitinib in PC9/GR and HCC827/GR cells as indicated treatment. ** p < 0.01, compared with PBS; # p < 0.05, compared with DMSO

Article Snippet: The β‐elemene injection (National Medical Product Administration Approval Number: Chinese medicine H10960114) was obtained from Dalian Huali Jingang Pharmaceutical (Dalian, China).

Techniques: Expressing

Journal: Thoracic Cancer

Article Title: FBP1 induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer

doi: 10.1111/1759-7714.14750

Figure Lengend Snippet: The working model describes the mechanism of FBP1. The expression of FBP1 was increased in gefitinib‐resistant lung cancer cells when stimulated by β‐elemene. The upregulation of FBP1 bound to STAT3 and inhibited the phosphorylation of STAT3, resulting in the altered expression of apoptosis‐related genes and leading to gefitinib sensitivity

Article Snippet: The β‐elemene injection (National Medical Product Administration Approval Number: Chinese medicine H10960114) was obtained from Dalian Huali Jingang Pharmaceutical (Dalian, China).

Techniques: Expressing, Phospho-proteomics

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Anti-Lung-Cancer Activity and Liposome-Based Delivery Systems of β -Elemene

doi: 10.1155/2012/259523

Figure Lengend Snippet: Chemical structure of β -Elemene.

Article Snippet: Afterwards, an injection preparation containing 85% β -elemene developed by CSPC Pharmaceutical Limited Cooperation (China) has been approved by the SFDA, China, for the treatment of brain tumours and other carcinomas [ ].

Techniques:

Journal: Oncology Reports

Article Title: β-elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A-VEGFA pathway based on network pharmacology

doi: 10.3892/or.2019.7360

Figure Lengend Snippet: Network of β-elemene-target genes. Red diamond represents β-elemene; blue circles represent target genes of β-elemene.

Article Snippet: Serial concentrations of β-elemene [CSPC Pharmaceutical Group Company Ltd. (YUANDA), Dalian, China] were added to the cells: 0, 0.5, 1, 2, 4, 8 and 16 µM.

Techniques:

Journal: Oncology Reports

Article Title: β-elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A-VEGFA pathway based on network pharmacology

doi: 10.3892/or.2019.7360

Figure Lengend Snippet: Thirty-three target genes for β-elemene against pancreatic cancer. (A) Venn diagram revealing the overlapping target genes for β-elemene against pancreatic cancer. (B) Network of target genes for β-elemene against pancreatic cancer. Red diamond represents β-elemene; red hexagon represents pancreatic cancer; blue circles represent target genes of both β-elemene and pancreatic cancer; yellow triangles represent KEGG pathway analysis of 33 target genes based on the DAVID database. KEGG, Kyoto encyclopedia of genes and genomes; DAVID, Database for Annotation, Visualization and Integrated Discovery.

Article Snippet: Serial concentrations of β-elemene [CSPC Pharmaceutical Group Company Ltd. (YUANDA), Dalian, China] were added to the cells: 0, 0.5, 1, 2, 4, 8 and 16 µM.

Techniques:

Journal: Oncology Reports

Article Title: β-elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A-VEGFA pathway based on network pharmacology

doi: 10.3892/or.2019.7360

Figure Lengend Snippet: Molecular docking simulation of β-elemene to HIF1A. Sticks represent the three-dimensional structure of β-elemene; surface represents the protein structure of HIF1A. HIF1A, hypoxia-inducible factor 1-α.

Article Snippet: Serial concentrations of β-elemene [CSPC Pharmaceutical Group Company Ltd. (YUANDA), Dalian, China] were added to the cells: 0, 0.5, 1, 2, 4, 8 and 16 µM.

Techniques:

Journal: Oncology Reports

Article Title: β-elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A-VEGFA pathway based on network pharmacology

doi: 10.3892/or.2019.7360

Figure Lengend Snippet: Antitumor effect of β-elemene in pancreatic cancer. (A) MTT assay revealed that cell viability was suppressed by β-elemene in PANC-1 cells in a dose-dependent manner. (B) MTT assay revealed that cell viability was suppressed by β-elemene in BxPC3 cells in a dose-dependent manner. (C and D) MTT assay revealed that cell viability was suppressed by β-elemene in cells isolated from peritoneum effusion of pancreatic cancer patients in a dose-dependent manner.

Article Snippet: Serial concentrations of β-elemene [CSPC Pharmaceutical Group Company Ltd. (YUANDA), Dalian, China] were added to the cells: 0, 0.5, 1, 2, 4, 8 and 16 µM.

Techniques: MTT Assay, Isolation

Journal: Oncology Reports

Article Title: β-elemene inhibits the generation of peritoneum effusion in pancreatic cancer via suppression of the HIF1A-VEGFA pathway based on network pharmacology

doi: 10.3892/or.2019.7360

Figure Lengend Snippet: Validation of the HIF1A-VEGFA pathway inhibited by β-elemene in pancreatic cancer. (A) Western blot analysis in PANC-1 and BxPC3 pancreatic cancer cell lines and (B) corresponding histogram of protein expression levels of HIF1A and VEGFA in PANC-1 and BxPC3 pancreatic cancer cells. Three independent biological replicates were performed and data are presented as the mean ± standard deviation. *P<0.05 and **P<0.01. NS, not significant. HIF1A, hypoxia-inducible factor 1-α; VEGFA, vascular endothelial growth factor A.

Article Snippet: Serial concentrations of β-elemene [CSPC Pharmaceutical Group Company Ltd. (YUANDA), Dalian, China] were added to the cells: 0, 0.5, 1, 2, 4, 8 and 16 µM.

Techniques: Western Blot, Expressing, Standard Deviation